145 related articles for article (PubMed ID: 35023167)
1. What is the clinical impact of staging and surveillance PET-CT scan findings in patients with bone and soft tissue sarcoma?
Lee L; Kazmer A; Colman MW; Gitelis S; Batus M; Blank AT
J Surg Oncol; 2022 Apr; 125(5):901-906. PubMed ID: 35023167
[TBL] [Abstract][Full Text] [Related]
2. PET-CT staging affects time to treatment in sarcoma.
Lee L; Kazmer A; Colman MW; Gitelis S; Batus M; Blank AT
Surg Oncol; 2022 May; 41():101732. PubMed ID: 35235893
[TBL] [Abstract][Full Text] [Related]
3. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
4. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
[TBL] [Abstract][Full Text] [Related]
5. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Musculoskeletal Cancers.
Broski SM
PET Clin; 2024 Apr; 19(2):217-229. PubMed ID: 38184453
[TBL] [Abstract][Full Text] [Related]
6. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
[TBL] [Abstract][Full Text] [Related]
7. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
8. Role of
Mercolini F; Zucchetta P; Jehanno N; Corradini N; Van Rijn RR; Rogers T; Cameron A; Scarzello G; Coppadoro B; Minard-Colin V; Gallego S; Chisholm J; Merks JH; Bisogno G
Eur J Cancer; 2021 Sep; 155():155-162. PubMed ID: 34385068
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?
Ulaner GA; Magnan H; Healey JH; Weber WA; Meyers PA
AJR Am J Roentgenol; 2014 Apr; 202(4):859-67. PubMed ID: 24660717
[TBL] [Abstract][Full Text] [Related]
13. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas.
Piperkova E; Mikhaeil M; Mousavi A; Libes R; Viejo-Rullan F; Lin H; Rosen G; Abdel-Dayem H
Clin Nucl Med; 2009 Mar; 34(3):146-50. PubMed ID: 19352275
[TBL] [Abstract][Full Text] [Related]
14. Utilization of positron emission tomography in the management of patients with sarcoma.
Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
[TBL] [Abstract][Full Text] [Related]
15. Molecular imaging of sarcomas with FDG PET.
Mendoza H; Nosov A; Pandit-Taskar N
Skeletal Radiol; 2023 Mar; 52(3):461-475. PubMed ID: 36173459
[TBL] [Abstract][Full Text] [Related]
16. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.
Katal S; Gholamrezanezhad A; Kessler M; Olyaei M; Jadvar H
PET Clin; 2018 Oct; 13(4):609-621. PubMed ID: 30219191
[TBL] [Abstract][Full Text] [Related]
17. PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma.
Kandathil A; Subramaniam RM
PET Clin; 2017 Oct; 12(4):475-488. PubMed ID: 28867117
[TBL] [Abstract][Full Text] [Related]
18. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients.
Fuglø HM; Jørgensen SM; Loft A; Hovgaard D; Petersen MM
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1416-24. PubMed ID: 22699526
[TBL] [Abstract][Full Text] [Related]
20. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
